Dyax Phase II angiodema results

(DYAX) said top-line results from the Phase II EDEMA1 Phase II trial showed its DX-88 met the primary endpoint of improvement in the symptoms of acute attacks of hereditary angioedema (HAE) within four hours of treatment. The double-blind, placebo-controlled trial was run in the U.S. and enrolled 48 patients with HAE. Earlier this month the FDA released a clinical hold on the company's Phase II EDEMA2 trial of DX-88 after DYAX and partner Genzyme (GENZ) answered questions about the sporadic deaths of rats seen in a previous toxicology study. ...